nach oben

Erschienen in:

14.07.2022 | Topic Paper

Micro-ultrasound-guided biopsies versus systematic biopsies in the detection of prostate cancer: a systematic review and meta-analysis

verfasst von: Charles Dariane, Guillaume Ploussard, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fromont, Mathieu Gauthé, Romain Mathieu, Raphaële Renard-Penna, Guilhem Roubaud, Alain Ruffion, Paul Sargos, Morgan Rouprêt, Gaëlle Fiard, the Prostate Cancer Committee of the Association Française d’Urologie (CC-AFU)

Erschienen in: World Journal of Urology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The diagnosis of prostate cancer (PCa) still relies on the performance of both targeted (TB) and systematic biopsies (SB). Micro-ultrasound (mUS)-guided biopsies demonstrated a high sensitivity in detecting clinically significant prostate cancer (csPCa), which could be comparable to that of magnetic resonance imaging (MRI)-TB, but their added value has not been compared to SB yet.

Methods

We conducted a systematic review and meta-analysis, based on Medline, EMBASE, Scopus, and Web of Science, in accordance with PRISMA guidelines, to compare mUS-guided biopsies to SB.

Results

Based on the literature search of 2957 articles, 15 met the inclusion criteria (2967 patients). Most patients underwent mUS-guided biopsies, followed by MRI-TB and SB. Respectively 5 (n = 670) and 4 (n = 467) studies, providing raw data on SB, were included in a random-effect meta-analysis of the detection rate of csPCa, i.e. Gleason Grade Group (GGG) ≥ 2 or non-csPCa (GGG = 1). Overall, PCa was detected in 56–71% of men, with 31.3–49% having csPCa and 17–25.4% having non-csPCa. Regarding csPCa, mUS-guided biopsies identified 196 and SB 169 cases (Detection Ratio (DR): 1.18, 95% CI 0.83–1.68, I² = 69%), favoring mUS-guided biopsies; regarding non-csPCa, mUS-guided biopsies identified 62 and SB 115 cases (DR: 0.55, 95% CI 0.41–0.73, I² = 0%), also favoring mUS-guided biopsies by decreasing unnecessary diagnosis.

Conclusion

Micro-ultrasound-guided biopsies compared favorably with SB for the detection of csPCa and detected fewer non-csPCa than SB. Prospective trials are awaited to confirm the interest of adding mUS-guided biopsies to MRI-TB to optimize csPCa detection without increasing overdiagnosis of non-csPCa.

Nur mit Berechtigung zugänglich

Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L et al (2020) French ccAFU guidelines—update 2020–2022: prostate cancer. Prog Urol 30(12S):S136-251CrossRefPubMed

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–77 (10 mai)CrossRefPubMedPubMedCentral

Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol janv 20(1):100–109CrossRef

Bryk DJ, Llukani E, Taneja SS, Rosenkrantz AB, Huang WC, Lepor H (2017) The role of Ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy. Urology avr 102:178–182CrossRef

Walz J (2018) The « PROMIS » of magnetic resonance imaging cost effectiveness in prostate cancer diagnosis? Eur Urol janv 73(1):31–32CrossRef

Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B et al (2016) Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification. J Urol août 196(2):562–569CrossRef

Sountoulides P, Pyrgidis N, Polyzos SA, Mykoniatis I, Asouhidou E, Papatsoris A et al. (2021) Micro-ultrasound-guided versus multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis. J Urol. (Sountoulides, Pyrgidis, Mykoniatis, Anastasiadis, Hatzichristou) Urology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece). 10.1097JU0000000000001639

Rodriguez Socarras ME, Gomez RJ, Cuadros RV, Reinoso EJ, Llanes GL, Michel Mercado I et al (2020) Prostate mapping for cancer diagnosis: the madrid protocol transperineal prostate biopsies using multiparametric magnetic resonance imaging fusion and micro-ultrasound guided biopsies. J Urol 204(4):726–33CrossRefPubMed

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed) 74(9):790–9CrossRefPubMed

10.

Egevad L, Delahunt B, Srigley JR, Samaratunga H (2016) International society of urological pathology (ISUP) grading of prostate cancer —an ISUP consensus on contemporary grading. APMIS juin 124(6):433–435CrossRef

11.

Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–36CrossRefPubMed

12.

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods [Internet]. 26 avr 2020 [cité 21 mai 2020];n/a(n/a). Disponible sur https://doi.org/10.1002/jrsm.1411

13.

Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 22(343):4002CrossRef

14.

Abouassaly R, Klein EA, El-Shefai A, Stephenson A (2020) Impact of using 29 MHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience. World J Urol 38(5):1201–1206CrossRefPubMed

15.

Avolio PP, Lughezzani G, Paciotti M, Maffei D, Uleri A, Frego N et al. (2021) The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: a single institutional analysis. Urol Oncol S1078–1439(21)00238–6

16.

Klotz L, Lughezzani G, Maffei D, Sánchez A, Pereira JG, Staerman F et al (2021) Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: a multicenter, prospective analysis. Can Urol Assoc J janv 15(1):E11–E16

17.

Luger F, Gusenleitner A, Kaar J, Mayr C, Loidl W (2019) Does 29Mhz micro-ultrasound provide uniform diagnostic accuracy within and beyond the peripheral zone? AUN https://doi.org/10.33552/AUN.2020.01.000519CrossRef

18.

Lughezzani G, Maffei D, Saita A, Paciotti M, Diana P, Buffi NM et al (2021) Diagnostic accuracy of microultrasound in patients with a suspicion of prostate cancer at magnetic resonance imaging: a single-institutional prospective study. Eur Urol Focus 7(5):1019–1026CrossRefPubMed

19.

Pereira-Arias JG, Sanchez-Vazquez A, Gamarra-Quintanilla M, Mora-Christian JA, Urdaneta-Salegui LF, Astobieta-Odriozola A et al (2019) Prostatic high resolution micro-ultrasound (MUS) imaging. Arch Esp Urol 72(8):804–815PubMed

20.

Claros OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, Muttin F, Carneiro A et al (2020) Comparison of initial experience with transrectal magnetic resonance imaging cognitive guided micro-ultrasound biopsies versus established transperineal robotic ultrasound magnetic resonance imaging fusion biopsies for prostate cancer. J Urol 203(5):918–925CrossRefPubMed

21.

Wiemer L, Hollenbach M, Heckmann R, Kittner B, Plage H, Reimann M et al. Evolution of targeted prostate biopsy by adding micro-ultrasound to the magnetic resonance imaging pathway. Eur Urol Focus. 9 juill 2020

22.

Hofbauer SL, Luger F, Harland N, Plage H, Reimann M, Hollenbach M et al (2022) A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer. BJU Int 129(5):648–654. https://doi.org/10.1111/bju.15635CrossRefPubMed

23.

Pavlovich CP, Cornish TC, Mullins JK, Fradin J, Mettee LZ, Connor JT et al (2014) High-resolution transrectal ultrasound: pilot study of a novel technique for imaging clinically localized prostate cancer. Urol Oncol janv 32(1):34.e27–32CrossRef

24.

Added Value of mpMRI and High-Resolution 29 MHz Micro-Ultrasound Targeting during Prostate Biopsy on Suspicion of Prostate Cancer.pdf [Internet]. [cité 30 juin 2021]. Disponible sur: https://www.exactimaging.com/images/POSTERS/Added%20Value%20of%20mpMRI%20and%20High-Resolution%2029%20MHz%20Micro-Ultrasound%20Targeting%20during%20Prostate%20Biopsy%20on%20Suspicion%20of%20Prostate%20Cancer.pdf

25.

2018_Poster_EAU 2018_Relative Sensitivity for Detecting CS-PCa via targeted biopsies of Micro-Ultrasound to MP-MRI.pdf [Internet]. [cité 30 juin 2021]. Disponible sur: https://www.exactimaging.com/images/POSTERS/2018_Poster_EAU%202018_Relative%20Sensitivity%20for%20Detecting%20CS-PCa%20via%20targeted%20biopsies%20of%20Micro-Ultrasound%20to%20MP-MRI.pdf

26.

Martel P, Tawadros T, Burruni R, Rakauskas A, Meuwly J-Y, Rosa SL et al. The utility of high-frequency micro-ultrasound in performing MRI-ultrasound fusion targeted biopsy 1

27.

Initial Results Comparing High-Resolution Micro-Ultrasound with Multiparametric MRI for Prostate Cancer Detection.pdf [Internet]. [cité 30 juin 2021]. Disponible sur: https://www.exactimaging.com/images/POSTERS/Initial%20Results%20Comparing%20High-Resolution%20Micro-Ultrasound%20with%20Multiparametric%20MRI%20for%20Prostate%20Cancer%20Detection.pdf

28.

You C, Li X, Du Y, Peng L, Wang H, Zhang X et al. The Micro-ultrasound guided prostate biopsy in detection of prostate cancer: a systematic review and meta-analysis. J Endourol. 25 sept 2021

29.

Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumiguié M et al (2020) The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. Eur Urol juin 77(6):733–741CrossRef

30.

Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT et al (2020) MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 382(10):917–28CrossRefPubMedPubMedCentral

31.

Correas J-M, Halpern EJ, Barr RG, Ghai S, Walz J, Bodard S et al (2021) Advanced ultrasound in the diagnosis of prostate cancer. World J Urol mars 39(3):661–676CrossRef

32.

Dias AB, O’Brien C, Correas JM, Ghai S (2022) Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review. Br J Radiol 95(1131):20210633. https://doi.org/10.1259/bjr.20210633CrossRefPubMed

33.

Regis F, Casale P, Persico F, Colombo P, Cieri M, Guazzoni G et al (2020) Use of 29-MHz micro-ultrasound for local staging of prostate cancer in patients scheduled for radical prostatectomy: a feasibility study. Eur Urol Open Sci 19:20–23CrossRefPubMedPubMedCentral

34.

Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M et al (2021) MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med 385(10):908–20CrossRefPubMed

35.

Vesval Q, Fiard G, Villers A, Norris JM, Olivier J (2021) Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? a review of literature. Prog Urol mars 31(3):147–157CrossRef

36.

Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER, et al. (2022) Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling. Eur Urol S0302–2838(22)00010–0

37.

Tschirdewahn S, Wiesenfarth M, Bonekamp D, Püllen L, Reis H, Panic A et al (2021) Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography-fusion biopsy. Eur Urol Focus 7(6):1300–1307CrossRefPubMed

38.

Rohrbach D, Wodlinger B, Wen J, Mamou J, Feleppa E (2018) High-frequency quantitative ultrasound for imaging prostate cancer using a novel micro-ultrasound scanner. Ultrasound Med Biol juill 44(7):1341–1354CrossRef

39.

Klotz L, Andriole G, Cash H, Cooperberg M, Crawford ED, Emberton M et al (2021) Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemp Clin Trials 112:106618CrossRefPubMed

Titel: Micro-ultrasound-guided biopsies versus systematic biopsies in the detection of prostate cancer: a systematic review and meta-analysis
verfasst von: Charles Dariane
Guillaume Ploussard
Eric Barret
Jean-Baptiste Beauval
Laurent Brureau
Gilles Créhange
Gaëlle Fromont
Mathieu Gauthé
Romain Mathieu
Raphaële Renard-Penna
Guilhem Roubaud
Alain Ruffion
Paul Sargos
Morgan Rouprêt
Gaëlle Fiard
the Prostate Cancer Committee of the Association Française d’Urologie (CC-AFU)
Publikationsdatum: 14.07.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 3/2023
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-022-04087-z

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Micro-ultrasound-guided biopsies versus systematic biopsies in the detection of prostate cancer: a systematic review and meta-analysis